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Objective To study the effect of an antiatherogenic diet on
maternal and cord blood concentrations of systemic biomarkers
of endothelial cell activation, haemostasis and inﬂammation.
Design Single blinded randomised controlled clinical trial.
Setting Obstetric outpatient clinic and maternity unit of
a university hospital in Norway.
Population Nonsmoking pregnant women aged 21–38 years
carrying a single fetus and with no previous pregnancy-related
complications.
Methods Subjects (n = 290) were randomised to continue their
usual diet or to adopt a diet low in saturated fat and cholesterol
from gestational week 17–20 to birth. Soluble forms of cellular
adhesion molecules, high-sensitivity C-reactive protein (CRP) and
haemostatic markers were measured at 17–20 weeks of gestation
(baseline) and subsequently up to week 36. All the above, except
CRP, were also measured in cord blood.
Main outcome measures Concentrations of maternal and fetal
biomarkers and maternal CRP.
Results All biomarkers except CRP levels increased signiﬁcantly
during the study period in both the intervention and control
groups. None of the maternal or fetal biomarkers were inﬂuenced
by the intervention (P > 0.05) except for a tendency to lower
concentrations of cord blood tissue plasminogen activator antigen
in the intervention group compared with the control group,
median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml
(3.5–11.8), P = 0.05.
Conclusion An antiatherogenic diet in pregnancy did not
signiﬁcantly inﬂuence maternal or fetal blood concentrations of
a range of biomarkers for inﬂammation. Thus, the previously
reported effects of a cholesterol-lowering diet on maternal lipid
proﬁle and preterm delivery (<37 complete weeks of gestation) do
not seem to involve changes in the systemic inﬂammatory
responses of pregnancy.
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Introduction
Complications of pregnancy, including pre-eclampsia, sponta-
neous loss of early pregnancy, low birthweight and preterm
delivery, have been linked to the maternal risk of coronary
heart disease in later life.1,2 Pathological changes in the utero-
placental circulation in pre-eclampsia and preterm deliv-
ery share common features with atherosclerosis.3,4 Adverse
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www.blackwellpublishing.com/bjog Maternal medicinepregnancy outcomes are also related to the infant’s cardiovas-
cular risk in later life.5,6 Moreover, maternal hypercholestero-
laemia is associated with fetal and childhood atherosclerosis.7,8
The Cardiovascular Risk Reduction Diet in Pregnancy
(CARRDIP) trial was a randomised clinical trial designed
to assess the effect of a low-cholesterol, low-saturated-fat
antiatherogenic diet compared with the usual diet among
nonsmoking white European healthy women on maternal,
cord and neonatal lipid concentrations, and on pregnancy
outcome. Maternal lipid concentrations were reduced in the
intervention arm of the trial, while cord blood and neonatal
lipids did not differ between the groups. The diet had no
measured adverse effects. However, there was a marked
reduction in the incidence of preterm delivery (a live birth
prior to 37 complete weeks of gestation) in the intervention
group. Gestational age was based on the ultrasound examina-
tion performed at week 17–18 of gestation. There were no
differences between the intervention and control groups with
respect to other pregnancy complications.9
Inﬂammatory mechanisms are involved in atherogenic
processes as well as in several pregnancy complications
including preterm delivery.10–13 These mechanisms may be
reﬂected in elevated blood concentrations of soluble adhesion
molecules (sCAMs), markers of inﬂammation and endothe-
lial activation, such as vascular adhesion molecule (VCAM-1)
and intercellular adhesion molecule (ICAM-1), as has often
been observed in pre-eclampsia.14–23 On the other hand, the
concentration of high-sensitivity C-reactive protein (CRP),
though emerging as a potential marker for cardiovascular
risk,24 has not been shown to differ signiﬁcantly in women
who subsequently develop pre-eclampsia or fetal growth
restriction compared with women with uncomplicated preg-
nancies.18,19 Furthermore, markers of prothrombotic activity
like von Willebrand’s factor (vWF) and markers of abnormal
ﬁbrinolysis including plasminogen activator inhibitor type 1
(PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plas-
minogen activator antigen (tPAag) have been identiﬁed as
independent markers of cardiovascular risk in several stud-
ies25–27 and have also been related to pregnancy outcome.20–23
Several studies in nonpregnant subjects have indicated that
diet inﬂuences concentrations of sCAMs and other novel car-
diovascular risk markers28–30 but have not been studied in
relation to dietary intervention in pregnancy. In this analysis
of the CARRDIP population, we investigated the effect of an
antiatherogenic diet on maternal and fetal (cord blood) con-
centrations of sCAMs, markers of thrombosis and ﬁbrinolysis
and on maternal levels of high-sensitivity CRP.
Methods
The trial has been described in detail previously.9 In brief,
290 healthy, nonsmoking, pregnant white European women
aged 21–38 years, without a previous or current pregnancy
complication and carrying a single healthy fetus, were rand-
omised to follow their usual diet or the intervention diet. The
randomisation list was generated from a table of random
numbers drawn up by the investigator (S.T.) who had no
contact with the pregnant women (as described previously).9
Sealed opaque envelopes consecutively numbered and con-
taining the randomisation number and code (control or
intervention) were given to the dietician responsible for giv-
ing the dietary advice. Thereafter, each screened and eligible
woman was allocated the next available number by the dieti-
cian who opened the envelope to determine whether the
woman was to follow the usual diet or the intervention diet.
The intervention diet aimed to limit dietary cholesterol and
to reduce the intake of saturated fat by replacing saturated fat
withmonounsaturatedandpolyunsaturatedfat.Women in the
interventiongroup(n=141)wereadvisedtoconsumeﬁsh,low-
fatmeats,oilsandlow-fatdairyproductsinsteadoffull-fatdairy
productsandmeats,andtoincreasetheirintakeofwholegrains,
fruits, vegetables and legumes. Both the intervention and con-
trolgroupsfollowedthesamescheduleofbloodsampling,phy-
sician and dietician visits and assessments (Figure 1). Usual
antenatal care was provided by the woman’s general physician
and/or midwife. The initial and all the follow-up examinations
pertainingtothestudywereconductedbyaspecialistinobstet-
ricsandgyanecology(J.K.).Thephysiciansandmidwivescaring
for the women, the specialist physician (J.K.) and all laboratory
and other personnel were blinded with regard to treatment
assignment. The subjects were asked not to reveal their dietary
assignment to any of the study staff or other subjects.
To assess dietary compliance, the weighed dietary intake
was recorded on a predetermined day weekly throughout preg-
nancy. The women were instructed in the cumulative weighing
technique using a digital dietary scale. All food and beverages
consumed were described and weighed. The dietary records
were entered into the database by certiﬁed personnel and
scored using the software program Beregn developed by the
Department of Nutrition, University of Oslo, and based on
the Norwegian food table (1995; National Nutrition Council).
Foods or recipes that were not part of the programme were
calculated and added. Vitamin or iron supplements were not
included in the analyses.
Laboratory methods
Blood samples for measuring the risk markers (hereinafter
referred to as biomarkers) were obtained at each visit after
an overnight fast of at least 10 hours. VCAM-1, ICAM-1 and
E-selectin were measured at 17–20 weeks of gestation (base-
line) and at weeks 30 and 36. High-sensitivity CRP was meas-
ured at baseline and at weeks 24, 30 and 36. PAI-1, PAI-2,
tPAag and vWF were measured at baseline and week 36. All
the above, except CRP, were also measured in cord blood.
Serum separated within 1 hour was used for determination
of VCAM-1, ICAM-1, E-selectin and CRP. Blood for the
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immediately placed on ice and centrifuged within 30 minutes
(maternal samples) to 1 hour (cord blood samples) for deter-
mination of PAI-1, PAI-2, tPAag and vWF. All samples were
kept frozen at –70 C until analysed.
Commercial methods were used for all analyses. sCAMs
were analysed with kits provided by R&D Systems Europe,
Abingdon, Oxon, UK, and the individual CAMs had the
following coefﬁcients of inter-assay variation (CV): VCAM-1,
5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%. High-sensitivity
CRP was measured by means of the Roche Modular electro-
chemoluminescence method. CVs were 8.0, 4.0 and 6.0%
at concentrations of 0.13, 1.18 and 17.0 mg/l, respectively.
Commercial methods were also used for analyses of the
haemostaticparametersasfollows:Spectrolyse/pLPAI-1(Bio-
poolAB,Umea ˚,Sweden;CV4.2%),ImubindPAI-2(American
Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize
tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago
Diagnostica, Asnieres, France; CV 8.0%).
Fatty acid measurements were carried out in serum frozen
immediately after venesection and stored at –70 C. A single
technician analysed all samples simultaneously after comple-
tion of the trial. Serum total fatty acid proﬁles were deter-
mined at baseline and at gestational week 36 by extracting
lipids from serum. After transesteriﬁcation, fatty acid methyl
esters were separated by means of capillary gas liquid chro-
matography. The identity of each fatty acid peak was ascer-
tained by comparison of the peak’s retention time relative to
the retention times of fatty acids in a synthetic standard of
known fatty acid composition. The relative amount of each
fatty acid (% of total fatty acid) was quantiﬁed by integration
of the area under the peak and dividing the result by the total
area for all fatty acids. All the analyses were performed at
the Department of Clinical Chemistry, National Hospital,
Oslo, under the supervision of Bjørn Christophersen.
Statistical analyses
The assessment of the effects of an antiatherogenic diet on
markers of maternal and fetal endothelial activation and
inﬂammation was part of the secondary hypotheses of the
CARRDIP study and part of the original protocol. The power
calculations were, however, based on our primary hypothesis
concerning the expected difference in maternal total choles-
terol levels at week 36 and neonatal total cholesterol levels in
the intervention versus the control groups.9 In brief, a sample
size of 130 women in each group was required to detect a
5% reduction in maternal total cholesterol and a change of
15% (about 0.22 mmol/l) in neonatal total cholesterol
levels between the two groups, (a = 0.05; b = 0.20) in the
intervention versus the control groups. A total inclusion of
300 participants was planned in case of dropouts. With an
expected rate of adverse pregnancy outcome of 25% (data
based on the Norwegian Birth Register), this number of
participants had about 65% power with a set at 0.05 to ﬁnd
a 50% increase in the occurrence of any adverse pregnancy
outcome.
Dietary energy and intake of macronutrients and food
stuffs during pregnancy were expressed as mean daily intake,
based on weighed recordings of intake from baseline to
week 36.
All group differences (intervention versus control group),
including baseline characteristics, were analysed by two-
sample t tests or Mann–Whitney U test, as appropriate. The
tests used are shown in the tables. The tPAag concentrations
Gestation week 17–20
*Diet assessment based on weighed records performed in both groups and advice to the intervention group.
Baseline
24 30 36 Delivery
Ultrasound screening
Randomisation
Blood sample Blood sample Blood sample Blood sample Cord blood
(arterial and venous)
Parturition records
48-hour recall *Dietician
hs-CRP hs-CRP hs-CRP hs-CRP
tPAag, vWf, PAI-1, PAI-2 tPAag, vWf, PAI-1, PAI-2
VCAM-1, ICAM-1, E-selection VCAM-1, ICAM-1, E-selection VCAM-1, ICAM-1, E-selection VCAM-1, ICAM-1, E-selection
tPAag, vWf, PAI-1, PAI-2
*Dietician *Dietician
Figure 1. Assessment and scheduling procedures.
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a Mann–Whitney U test was used. However, due to the
numerical differences shown in the percentiles (Table 4), an
additional analysis based on the lognormal transformation of
tPAag was carried out. The transformed data were compared
by a two-sample t test.
Boxplots were used to describe the concentrations of the bio-
markers at different time points during the study period. CRP
values higher than 10 mg/l were excluded because of a number of
confounding causes of elevated CRP.24 The number of excluded
cases due to elevated CRP in the control and intervention
groups, respectively, were as follows: n = 24 and 11 at baseline,
n = 10 and 12 at week 24, n = 15 and 10 at week 30 and n =1 1
and 11 at week 36. The Wilcoxon test for paired samples was
used to test changes from baseline to week 36 within the
intervention and control groups and in the cohort as a whole.
Pearson’s correlation coefﬁcient was used to assess corre-
lation between baseline CRP and baseline body mass index
(BMI) in the entire cohort before randomisation. All analyses
were performed using the software program SPSS version
12.0. A two-sided P value <0.05 was considered statistically
signiﬁcant.
Results
The intention-to-treat cohort included 290 women. Of these,
149 were randomised to continue their usual diet (control)
and 141 were randomised to the intervention diet. Main base-
line characteristics of the participants are shown in Table 1.
No differences in baseline characteristics or dietary variables
between the groups were observed before randomisation.9
Dietary adherence
Based on dietary records of weighed intake from baseline to
gestation week 36, the intervention group consumed less
energy and total fat than the control group.9 This was due
to a lower intake of saturated fat and dietary cholesterol.9
Compared with the control group, the intervention group
signiﬁcantly reduced their intake of fatty milk and meat prod-
ucts and signiﬁcantly increased their intake of ﬁsh and ﬁsh
products. Mean dietary intake of fatty ﬁsh and ﬁsh products
during the study period was also signiﬁcantly higher in the
intervention group compared with the control group
(Table 2). In addition, the intervention group increased their
use of monounsaturated oils, mainly olive oil and rapeseed
oil. Moreover, the consumption of nuts, olives, seeds, fruits
and vegetables was signiﬁcantly higher in the intervention
group compared with the control group (Table 2).
The increase in myristic acid (C14:0) level in serum total
fatty acids from baseline to week 36 was signiﬁcantly lower
in the intervention group compared with the control group,
while eicosapentaenic acid (C20:5) levels tended to increase
more in the intervention than in the control group (Table 3).
Maternal biomarkers and the dietary
intervention
Over the duration of the study period (between baseline and
week 36), there was a signiﬁcant increase in the concentra-
tions of sCAMs and the haemostatic markers both within
the intervention and control groups analysed separately
(Figures 2 and 3; P < 0.01forallvariables)andwithin the entire
cohort (data not shown; P < 0.01 for all variables). However,
the concentrations of CRP did not increase within the inter-
vention and control groups analysed separately (Figure 2d,
P > 0.1) or as an entire cohort (data not shown, P > 0.1).
Concentrations of sCAMs, CRP and the haemostatic markers
did not differ between the control and intervention groups
(Figures 2 and 3, P values are shown with each boxplot and
refer to group differences for changes in those markers from
gestation week 17–20 [baseline] to gestation week 36). In the
total study population (control and intervention groups com-
bined), a positive significant correlation was found between
baseline CRP and baseline BMI (r = 0.27, P = 0.01).
Biomarkers in cord blood
Concentrations of fetal sCAMs and haemostatic markers
in cord blood did not differ between the groups, with the
exception of tPAag concentrations, which tended to be
numerically lower in the intervention group compared
with the control group (Table 4; a two-sample t test on
lognormal-transformed values of tPAag gave a P value of
0.05 for the difference between the groups).
Discussion
In this randomised controlled trial (Figure 4) of healthy white
European subjects carrying singleton pregnancies, we found
no effect of an antiatherogenic diet on maternal concentra-
tions of sCAMs, CRP and haemostatic parameters (PAI-1,
Table 1. Characteristics of participants at baseline
Characteristic Control Intervention P-value
No. 149 141
Age (years) 29.8 (3.4) 29.6 (3.7) 0.7
Nulliparous (%) 65.1 70.9 0.3
Gestational age
at entry (week)
19 (1.1) 19 (1.1) 0.9
19 (5.4)* 19 (4.9)*
BMI (kg/m2) 24.3 (2.7) 24.3 (2.9) 0.9
BMI (%) .25 (kg/m2) 32.9 36.2 0.6
Systolic blood
pressure (mmHg)
105 (10) 106 (9) 0.9
Diastolic blood
pressure (mmHg)
65 (8) 64 (8) 0.4
Values are mean (SD).
*Median (range).
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control groups. Moreover, no differences were found between
the groups in concentrations of the fetal blood variables meas-
ured other than a tendency to lower concentrations of tPAag
in the intervention group. Thus, the previously reported pre-
ventive effect of the current dietary intervention on preterm
delivery is not likely to involve modiﬁcation of systemic
inﬂammatory biomarkers.
To our knowledge, the effect of a dietary intervention on
markers of endothelial activation and inﬂammation has not
been studied previously in women of fertile age or during
pregnancy. The reported signiﬁcant differences in dietary
saturated and unsaturated fat intakes between the groups
are supported by the observed difference in some serum fatty
acid levels (myristic, eicosapentaenic) between the interven-
tion and control groups. Dietary counselling, similar to the
Table 2. Mean (SD) daily dietary intake from weighed food records during the study period
Control diet (n 5 141) Intervention diet (n 5 127) P value
Total energy (kcal/day) 2189 (335) 2031 (348) ,0.001
Total fat (% of energy) 32.3 (3.4) 30.0 (4.1) ,0.001
Protein (% of energy) 14.7 (1.5) 15.6 (1.6) ,0.001
Carbohydrates (% of energy) 52.3 (3.7) 53.7 (4.3) 0.004
Sugar (% energy) 11.6 (4) 9.1 (4.3) ,0.001
Milk and milk products (g/day) 457 (172) 415 (165) 0.05
Fatty milk (g/day) 27 (40) 14.2 (18.1) ,0.001
Cheese (g/day) 37.1 (16.2) 33.2 (17) 0.07
Meat and meat products (g/day) 91.5 (28.9) 75.2 (27.8) ,0.001
Fatty minced meat (g/day) 7.5 (9) 3.6 (6.1) ,0.001
Fish and ﬁsh products (g/day) 48.6 (27.1) 61.8 (24.5) ,0.001
Fatty (ﬁsh and products) 16.0 (14.6) 25.2 (16) ,0.001
Butter (g/day) 3.8 (4.7) 0.97 (2.1) ,0.001
Hard margarines (g/day) 1.0 (1.4) 0.4 (1.0) ,0.001
Soft margarines (g/day) 16.6 (8.1) 16.1 (9.4) 0.7
Rapeseed-based margarine 0.97 (2.3) 6.2 (5.1) ,0.001
Oils (g/day) 3.6 (5.1) 8 (4.8) ,0.001
Olive oil 1.7 (2.5) 6.8 (4.5) ,0.001
Rapeseed oil 0.3 (1.0) 1.4 (1.8) ,0.001
Nuts, olives and seeds (g/day) 3.7 (5.1) 7.6 (7.5) ,0.001
Vegetables (g/day) 139 (57.5) 165 (66.5) 0.001
Fruits (g/day) 407 (147) 471 (171) 0.002
T-test for group differences.
Table 3. Fatty acid composition (% of total serum fatty acids) at baseline and week 36
Control (n 5 129) Intervention (n 5 125) P*
Baseline Week 36 Baseline Week 36
C14:0 0 (0, 0) 0 (0, 0.7) 0 (0, 0) 0 (0, 0.6) 0.02
C14:0** 0.15 (0.33) 0.35 (0.39) 0.18 (0.33) 0.28 (0.38)
C16:0 26.5 (25.3, 28.1) 29.5 (28.1, 31.4) 26.5 (25.2, 27.9) 29.3 (27.5, 31.0) 0.4
C18:0 7.5 (6.7, 8.1) 7.2 (6.3, 7.8) 7.6 (6.9, 8.1) 7.0 (6.5, 7.6) 0.1
C18:1 21.1 (19.6, 22.5) 21.8 (20.3, 24.0) 20.7 (19.2, 22.2) 22.2 (20.5, 24.2) 0.3
C18:2 27.6 (25.4, 29.9) 25.6 (24.3, 28.6) 27.7 (25.3, 30.6) 26.3 (24.4, 28.6) 0.7
C18:3 0.7 (0, 0.8) 0.7 (0.5, 0.8) 0.7 (0, 0.8) 0.7 (0, 0.8) 0.8
C20:4 7.0 (6.1, 7.8) 5.9 (5.2, 6.7) 6.9 (6.2, 7.9) 5.9 (5.1, 6.7) 0.1
C20:5 0.9 (0.4, 1.4) 0.6 (0, 1.0) 1.0 (0, 1.5) 0.7 (0,1.4) 0.06
C22:6 7.6 (5.9, 9.6) 6.5 (4.7, 8.5) 7.6 (5.9, 9.4) 6.7 (5.0, 8.5) 0.7
Data are shown as median (25,75 percentiles), except for C14:0 where **mean (SD) values are supplemented.
*Mann–Whitney U test for the change from baseline to week 36.
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extended over a 3-year interval, has been shown to reduce
ICAM and tPAag concentrations in a randomised trial of
men aged 65–75 years.29
The lack of effect of an antiatherogenic diet in pregnancy
on markers of endothelial activation and inﬂammation may
be limited to the current study population, which consisted
of healthy, nonsmoking pregnant women with no previous
pregnancy complications. There is also a possibility of type
II error since power analysis was carried out in regard to
the primary hypothesis i.e. reducing maternal and neonatal
total cholesterol levels.9 The major strength of the CARR-
DIP study, on the other hand, is that it is a randomised
dietary intervention trial in pregnancy with a prospective
design. In addition, the different dietary intake between the
groups was veriﬁed through characterisation of the serum
fatty acid proﬁle.
Maternal concentrations of low-density lipoprotein (LDL)
cholesterol increased through gestation as expected,9 but
the observed decrease in LDL cholesterol concentrations in
the intervention arm9 was not accompanied by lower CRP
concentrations in this group. It is, therefore, notable that
the signiﬁcant increase in all other systemic parameters of
inﬂammation through the study period, in accordance with
previous literature,12,15,20,22 was not observed with regard to
CRP concentrations, which remained essentially unchanged
(Figure 2d). We have not identiﬁed any previously published
longitudinal studies of CRP levels in pregnancy. CRP con-
centrations at 13 weeks of gestation are highly correlated
with pre-pregnancy adiposity.31 Our ﬁndings concerning the
signiﬁcant positive correlation between baseline CRP and
baseline BMI in the entire cohort suggest that adiposity is a
factor inﬂuencing the level of CRP in pregnancy, as seen in
nonpregnant populations.
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Figure 2. Boxplot for the concentrations of sCAMs and high-sensitivity (Hs) CRP (CRP values >10 not included) during the study period in the
control and intervention groups. P values refer to group differences expressed as changes in those markers from gestation week 17–20 (baseline)
to gestation week 36.
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factors are reported to increase,32 and our results agree with
previous observations. Fibrinolytic activity diminishes as tis-
sue plasminogen activator activity decreases, probably due to
the increase in the plasminogen activator inhibitors PAI-1
and PAI-2.32 We observed increases in concentrations of
tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in
both the control and intervention groups. However, the
Control Intervention Control Intervention
Control Intervention Control Intervention
0
5
10
15
20
25
30
35
40 tPAag (ng/ml) at baseline
tPAag (ng/ml) at week 36, P = 0.84
50
100
150
200
250
300
350
400 VWF (%) at baseline
VWF (%) at week 36, P = 0.12
(a) (b)
(c) (d)
0
10
20
30
40
50
60
70
80 PAI-1 activity (U/ml) at baseline
PAI-1 activity (U/ml) at week 36, P = 0.09
0
50
100
150
200
250
PAI-2 antigen (ng/ml) at baseline
PAI-2 antigen (ng/ml) at week 36, P = 0.07
Figure 3. Boxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and
intervention groups. P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline)
to gestation week 36.
Table 4. Concentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groups
No. control/intervention Control Intervention P value*
VCAM-1 (ng/ml) 120/119 813 (695, 970) 836 (715, 993) 0.4
ICAM-1 (ng/ml) 120/119 149 (130, 167) 148 (128, 174) 0.7
E-selectin (ng/ml) 120/118 150 (96.7, 189) 159 (123, 201) 0.08
tPAag (ng/ml) 119/117 5.8 (3.5, 11.8) 5.4 (3.1, 7.7) 0.2
vWF (%) 107/104 91 (66, 135) 82 (54, 120) 0.3
PAI-1 activity (u/ml) 118/115 9.3 (4.6, 17.8) 10.3 (5, 19) 0.6
PAI-2 antigen (ng/ml) 119/114 3.4 (1.1, 9.4) 3.7 (1.9, 6.7) 0.6
Values shown are median (25, 75 percentiles).
*Mann–Whitney U test for group differences.
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cates that lowering total and LDL cholesterol concentrations
in low-risk pregnancies by lowering dietary saturated fat9 is
not accompanied by changes in haemostatic variables, at least
not within the range of LDL lowering achieved in the present
study.
Inﬂammatory processes have been shown to take place
locally in the uteroplacental unit, especially in pre-eclampsia.33
Such local inﬂammatory processes may also occur in
some cases of preterm delivery, since it has been shown that
failure of physiological transformation and atherosis of the
uteroplacental spiral arteries are often seen in cases of preterm
delivery and bear several similarities to atherosclerosis in gen-
eral, including lipid deposition and inﬂammatory features.3,4
Moreover, increased concentrations of ICAM-1 in cervicova-
ginal ﬂuid have been considered as a potential predictor of
preterm delivery in women with symptoms of preterm
labour.34 Although we did not ﬁnd signiﬁcant changes in
the blood concentrations of the measured inﬂammatory
markers, we cannot exclude the possibility that the dietary
intervention somehow may have lead to changes in the local
uteroplacental or cervical inﬂammatory response involving,
for example, less enhanced leukocyte/endothelial interaction.
Whether lowering of maternal LDL cholesterol is directly
involved in initiating a local anti-inﬂammatory response
remains a hypothesis.
Another ﬁnding, which supports the notion of a possible
local effect in the intervention group, is that we observed
a tendency towards lower concentrations of fetal tPAag in
cord blood of fetuses born to mothers in the intervention
compared with the control group. To our knowledge, cord
blood tPAag concentrations are not described in the
literature. tPAag is regarded a marker of atherosclerotic
activity and to be an independent marker of coronary heart
disease.25,35 The effect of the diet on concentrations of tPAag
in fetal blood is in accordance with the intervention study of
Hjerkinn et al.29 However, we suggest that future studies
attempting to assess a possible local effect of the intervention
diet should include power calculations for tPAag in cord
blood as a primary hypothesis.
In conclusion, we found no effect of an antiatherogenic diet
during pregnancy on biomarkers of endothelial activation,
inﬂammation and haemostasis. All biomarkers increased
during the study period except for CRP, which was stable.
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Figure 4. Trial proﬁle.9
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nancy on maternal lipid proﬁle and risk of preterm delivery
do not seem to involve changes in the systemic inﬂammatory
responses of pregnancy.
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